PDF(Pubmed)
Abstract：
Autoimmune inflammation is caused by the loss of tolerance to specific self-antigens and can result in organ-specific or systemic disorders. Systemic autoimmune diseases affect a significant portion of the population with an increasing rate of incidence, which means that is essential to have effective therapies to control these chronic disorders. Unfortunately, several patients with systemic autoimmune diseases do not respond at all or just partially respond to available conventional synthetic disease-modifying antirheumatic drugs and targeted therapies. However, during the past few years, some new medications have been approved and can be used in real-life clinical settings. Meanwhile, several new candidates appeared and can offer promising novel treatment options in the future. Here, we summarize the newly available medications and the most encouraging drug candidates in the treatment of systemic lupus erythematosus, rheumatoid arthritis, Sjögren\'s disease, systemic sclerosis, systemic vasculitis, and autoimmune myositis.
摘要：
自身免疫性炎症是由对特异性自身抗原的耐受性丧失引起的,并且可导致器官特异性或全身性病症。系统性自身免疫性疾病影响了很大一部分人群，发病率越来越高，这意味着必须有有效的治疗方法来控制这些慢性疾病。不幸的是,一些全身性自身免疫性疾病患者对现有的常规合成疾病缓解抗风湿药和靶向治疗没有反应或只是部分反应.然而,在过去的几年里，一些新的药物已被批准，可用于现实生活中的临床环境。同时,出现了几个新的候选药物,并且可以在未来提供有希望的新的治疗选择.这里,我们总结了治疗系统性红斑狼疮的新药物和最令人鼓舞的候选药物，类风湿性关节炎,Sjögren病,系统性硬化症,全身性血管炎,和自身免疫性肌炎.
